Summary & Overview
HCPCS J7202: Idelvion (Factor IX Albumin Fusion Protein) Injection
HCPCS Level II code J7202 denotes the injectable recombinant factor IX albumin fusion protein idelvion, reported per international unit. This product provides factor IX replacement for patients with hemophilia B and is administered as an infused biologic therapy. Nationally, biologic factor replacement codes like J7202 are important for specialty pharmacy billing, hospital outpatient and infusion center reimbursement, and tracking high-cost drug utilization.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service settings, benchmarks and utilization considerations where available, and policy and billing elements that commonly affect coverage and claim adjudication for high-cost infused biologics.
This publication summarizes what J7202 represents, the typical sites of service for administration, payer coverage landscape, and common billing parameters. Data not available in the input is identified as such; the narrative focuses on national implications for hospital outpatient departments, ambulatory infusion centers, and specialty clinics that manage hemophilia B therapy.
Billing Code Overview
HCPCS Level II code J7202 represents an injection of recombinant factor IX albumin fusion protein (idelvion) measured per international unit (1 i.u.). This biologic therapeutic is used to provide factor IX replacement therapy for patients with hemophilia B.
Service type: injectable biologic therapy
Typical site of service: hospital outpatient infusion center, ambulatory infusion center, or specialty clinic
Clinical & Coding Specifications
Clinical Context
A 28-year-old male with moderate-to-severe congenital hemophilia B presents to an infusion center for routine factor replacement to prevent or treat bleeding. The patient receives a prescribed dose of recombinant factor IX albumin fusion protein (J7202) administered via intravenous infusion. The clinical workflow includes pre-infusion nursing assessment (vital signs, review of recent bleeding events, inhibitor testing if indicated), verification of the physician order and lot/expiration of the product, calculation of units required based on weight and target factor IX activity, venous access assessment, product reconstitution per manufacturer instructions, administration by an experienced infusion nurse, observation for infusion reactions for at least 30 minutes post-infusion, and documentation of lot number, units administered, start/stop times, and any adverse events.
Common settings for this service include hospital outpatient infusion centers, specialty hematology clinics, and home infusion under a home health or specialty pharmacy arrangement. Typical payor interactions include prior authorization for J7202, documentation of diagnosis linking to hemophilia B or other factor IX deficiency, and use of appropriate modifiers to indicate circumstances such as partial administration, wasted product, or administration by a different provider type.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|